The January 2009 issue of the Journal of Commercial Biotechnology is now available. This issue is available as a free preview for the time being, so dive in and read the papers. The links below will take you to the abstract for each paper:

Volume 15, Issue 1

Biotechnology commercialisation: Getting past the technology-push
Yali Friedman

Teaming in biotechnology commercialisation: The diversity-performance connection and how university programmes can make a difference
Anne S York, Kim A McCarthy and Todd C Darnold

NIH assistance for new therapeutic development: NIH-RAID Pilot Program
David G Badman

Record integrity and licensing your intellectual property
John Avellanet

Parallel imports: Towards a flexible uniform international rule
Stefan M Miller

Pharmaceutical patents after KSR: What is not obvious?
Jason Lief and Peter Schuyler

ATMP in practice: Towards a new industry landscape in tissue engineering
Laure Brévignon-Dodin and Pawanbir Singh

Thailand biotech business: Product of the national policy
Nataporn Chanvarasuth and Ramjitti Indaraprasirt

Legal and Regulatory Update

Science lessons: What biotech taught me about management
Arthur A Boni

Essentials of pharmacoeconomics
Harley King

Last week I sent an update to my list of biotech educators about the availability of instructor resources for Building Biotechnology. I’m starting to see interest among educators who I didn’t email, so I ‘m posting a follow-up here to spread the word.

The instructor resources are free for qualified educators and include figures and tables from the text, and sample lectures. Slide decks based on each chapter are also available for a fee, and a quiz bank will be posted shortly.

The instructor resources can be accessed at here, more information on Building Biotechnology is available at here, and the list of schools which have adopted the text is here

Volume 14, Issue 4

Continuing education in biotechnology
Yali Friedman

Open content textbooks: Educating the next generation of bioentrepreneurs in developing economies
Arlen D Meyers, Donald J McCubbrey and Richard T Watson

Can compliance help marketing and business development?
John Avellanet

Money for nothing? Risks in biopharmaceutical companies from the perspective of public financiers
Laura Heinonen and Birgitta Sandberg

Got value? Determine it. Demonstrate it. Communicate it. Realise it
Mitch DeKoven, Elisabeth H Hazard, Erica Goldberg and Shibani Pokras

Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development – Commonalities and differences in portfolio management practice
Kerstin M Bode-Greuel and Klaus J Nickisch

Legal and Regulatory Update

Intellectual Property and Biotechnology: Biological Inventions
Stefan M Miller

Commercializing Successful Biomedical Technologies
Arlen D Meyers

Enterprise for Life Scientists: Developing Innovation and Entrepreneurship in the Biosciences
Arlen D Meyers

Biotechnology and the Law
Edward L Korwek

Welcome to Biotech Nation
James Rogers

The Regulatory Challenge of Biotechnology
John Avellanet

Best Practices in Biotechnology Business Development
Hans-Erik Hamid Lydecker

Genetic Glass Ceilings: Transgenics for Crop Biodiversity
Drew L Kershen

Homewood Campus
Friday, Oct. 17th 2008 5:30-7:30pm
Remsen Hall Rm 101
3400 North Charles Street

East Baltimore Campus
Wednesday, Oct. 22nd 2008 5:30-7:30pm
Wood Basic Science Auditorium
725 Wolfe Street

Signed copies of my books will also be available for sale. For more details, contact connect@hopkinsbiotechnetwork.org.

• Marketing
• IP management
• R&D management
• Communications
• etc.

If you are interested in leading one of these projects and editing a topical compilation, please visit the Logos Press Submission Guidelines and tell me about your vision.

460 pages Hardcover:978-09734676-5-9 Hardcover:978-09734676-6-6 Third Edition August, 2008 Homepage

Building Biotechnology Business, Regulations, Patents, Law, Politics, Science The definitive primer and leading textbook on the business of biotechnology is now available in its third edition. This new edition is over 100 pages longer than the second edition and adds new chapters, new figures and tables, and additional case examples. Building Biotechnology builds a robust foundation by providing a comprehensive fundamentals-based overview of the broad variety of elements influencing the commercialization of biotechnology. Expanding on this foundation to ensure a practical appreciation of operational issues in the biotechnology industry, Building Biotechnology adds real-world examples on topics such as the hidden pitfalls of common operational decisions, practical considerations in selecting business models and funding options, strategies to overcome developmental failures, and methods to leverage options to strengthen development plans.

This new book is complemented by these existing titles:

First Edition, March 2008 Perfect Bound, 342 pages, US$74.95 ISBN: 978-09734676-7-3 Homepage Amazon	Best Practices in Biotechnology Education 22 International Best Practices in K-12, College, Certificate, Master’s, Doctoral, MBA, Distance Education Programs and Student Groups This international compilation is directed at faculty and program directors seeking to start or expand biotechnology education programs; policy makers and economic developers seeking to meet workforce needs; and, students, scientists, and business professionals looking to enter the biotechnology industry or upgrade their existing skills. The included cases describe a wide variety of international programs from high-school through Ph.D. levels, and student clubs. Some programs are in their first years whereas others are quite mature and have diversified to offer myriad degree and certificate programs.
First Edition, March 2008 Perfect Bound, 186 pages, US$67.95 ISBN: 978-09734676-0-4 Homepage Amazon	Best Practices in Biotechnology Business Development Valuation, Licensing, Cash Flow, Pharmacoeconomics, Market Selection, Communication, and Intellectual Property Best Practices in Biotechnology Business Development provides a framework to understand critical issues in biotechnology business development. Experts from a wide range of disciplines have contributed best practices based on their experiences and expertise, enabling biotechnology entrepreneurs, senior managers, directors, and officers to develop a better understanding of the key elements in these operations, empowering them to better manage their implementation.

The material is largely drawn from my book, Building Biotechnology. Go ahead and post any questions you may have in the comments.

Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM

Hope to see you there!

Volume 14, Issue 2
Editorial
Yali Friedman

A new approach to improve technology commercialisation in university medical schools
Courtney Price, Richard Huston and Arlen D Meyers

Export compliance for life sciences
John Avellanet

Biotechnology business models work: Evidence from the pharmaceutical marketplace
J Leslie Glick

Valuing biotechnology companies: Does classification by technology type help?
Jacqueline Loh and Robert Brooks

Risk management for the biotechnology industry: A Canadian perspective
Sandra Vanderbyl and Sherry Kobelak

Singapore’s biomedical sciences landscape
Keat-Chuan Yeoh

Social responsibility for the use of genes, genomes and biotechnology in biotechnology companies: A commentary from the bioethical viewpoint
Yoshihiro Okada and Kazuo N Watanabe

Legal & Regulatory Update
Bird & Bird and Reed Smith

Maryland and Virginia unite at 2007 Mid-Atlantic Bio Conference
Harley King

Book Review — Stem Cell Wars: Inside Stories from the Frontlines
Grant H Skrepnek

The Journal of Commercial Biotechnology is online at http://www.palgrave-journals.com/jcb. If purchasing a subscription, please use subscriber code NH0707G01.